Q1 Earnings Estimate for ChromaDex Issued By HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for ChromaDex in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of $0.03 for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for ChromaDex’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.29 EPS.

A number of other analysts have also recently issued reports on CDXC. LADENBURG THALM/SH SH lifted their price objective on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research report on Wednesday, March 5th. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 6th.

ChromaDex Trading Down 1.4 %

CDXC opened at $7.72 on Wednesday. The stock has a market cap of $600.23 million, a price-to-earnings ratio of 772.77 and a beta of 2.21. ChromaDex has a 1 year low of $1.98 and a 1 year high of $9.18. The stock has a fifty day moving average price of $5.96 and a 200 day moving average price of $5.30.

Institutional Trading of ChromaDex

Several large investors have recently made changes to their positions in CDXC. OneDigital Investment Advisors LLC boosted its stake in shares of ChromaDex by 5.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after acquiring an additional 3,097 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in ChromaDex by 10.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company’s stock valued at $639,000 after purchasing an additional 17,115 shares during the period. The Manufacturers Life Insurance Company boosted its stake in ChromaDex by 75.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company’s stock valued at $72,000 after purchasing an additional 8,485 shares during the period. Millrace Asset Group Inc. bought a new stake in ChromaDex during the 3rd quarter valued at approximately $93,000. Finally, FMR LLC bought a new stake in ChromaDex during the 3rd quarter valued at approximately $55,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.